DigestRedComo funciona
Red
/
Empresas
Mi
No verificado

Mirum Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosMercado de valoresSalud

66 Comunicados de prensa

Ver todos los comunicados de prensa
12/03/2026
Mercado de valores
Finanzas
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/03/2026
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/02/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
23/02/2026
Eventos
Web y redes sociales
Salud
Farmacéutica
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Salud
Biotecnología
Sanidad
Ciencia
Farmacéutica
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
11/02/2026
Biotecnología
Farmacéutica
Salud
Finanzas
Mercado de valores
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/02/2026
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/02/2026
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Farmacéutica
Salud
Industria
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/01/2026
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado de valores
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
12/01/2026
Biotecnología
Farmacéutica
Salud
Mercado de valores
Finanzas
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0